FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W88335433> ?p ?o ?g. }

• W88335433 abstract "Prostate cancer is the most commonly diagnosed malignancy and the second leading cause of cancer related deaths in Australian men. Treatment in the early stages of the disease involves surgery, radiation and/or hormone therapy. However, in late stages of the disease these treatments are no longer effective and only palliative care is available. Therefore, there is a focus on exploration of novel therapies to increase survival and treatment efficacy. Advanced prostate cancer is characterised by bone or other distant metastasis. Spreading of the primary tumour to a secondary location is a complex process requiring an initial loss in cell-cell adhesion followed by increased cell migration and invasion. One gene family that has been known to affect cell-to-cell contact in other model systems are the Eph receptor tyrosine kinases. They are the largest family of receptor tyrosine kinases made up of 14 vertebrate Eph receptors that bind to nine cell membrane bound ephrin ligands. Eph-ephrin interaction is crucial in regulating cell behaviour in developmental processes and it is now thought that the underlying mechanisms involved in development may also be involved in cancer. Aberrant expression has been reported in many human malignancies including prostate cancer. Furthermore, expression has been linked with metastasis and poor prognosis in other tumour models. This study explores the potential role of the Eph receptor family in prostate cancer, in particular the roles of EphA2, EphA3 and ephrin-A5.Gene expression profiles were established for the Eph family in a series of prostate cancer cell lines using quantitative real time RT-PCR. A smaller subset of the most prominently expressed genes was chosen to screen a cohort of clinical samples. Elevated levels of EphA2, EphA3 and their ligands, ephrin-A1 and ephrin-A5 were observed in individual cell lines. Interestingly high EphA3 expression was observed in the androgen responsive cell lines while EphA2 was more prominent in the androgen independent cell lines. However, studies using 5-dihydrotestosterone suggest that EphA3 expression in not regulated by androgen. Cells expressing EphA2 showed a greater ability for migration and invasion while cells expressing EphA3 showed poor migration and invasion. Forced expression of EphA2 in the LNCaP cell line resulted in a more invasive phenotype while forced expression of EphA3 in the PC-3 cell line suggests a possible negative effect for EphA3 on cell migration and invasion.Cell signalling studies show activation of EphA2 decreases activity of proteins thought to be involved in pathways regulating cell movement including Akt, Src and FAK. Changes to the activation status of Rho family members, including RhoA and Rac1, associated with reorganisation of the actin cytoskeleton, an important part of cell migration was also observed. As a result, activation of EphA2 in PC-3 cells resulted in a less invasive phenotype. A novel finding in this study was the discovery of a combination of two EphA2 Mabs able to activate EphA2. Preliminary results show a potential for this antibody combination to reduce prostate cancer invasion in vitro.A unique aspect of Eph-ephrin interaction is the resulting bi-directional signalling that occurs through both the receptor and ligand. In this study a potential role for ephrin-A5 mediated signalling in prostate cancer was observed. LNCaP cells express high levels of EphA3 and its high affinity ligand ephrin-A5. In stripe assays, used to study guidance cues, LNCaP cells show strong attraction/migration to EphA3-Fc stripes but not ephrin-A5-Fc stripes suggesting ephrin-A5 mediated reverse cell signalling is involved. Knockdown of ephrin-A5 using shRNA resulted in a decrease in attraction/migration to EphA3-Fc stripes. Furthermore a reduction in proliferation was also observed in vitro. A subcutaneous xenograft model using ephrin-A5 shRNA cells versus controls showed a decrease in tumour formation.This study demonstrates a difference in EphA2 and EphA3 function in prostate cancer migration/invasion and a potential role for ephrin-A5 in prostate cancer cell adhesion and growth." @default.
• W88335433 created "2016-06-24" @default.
• W88335433 creator A5040108414 @default.
• W88335433 date "2011-01-01" @default.
• W88335433 modified "2023-09-23" @default.
• W88335433 title "The role of the Eph and ephrin proteins in prostate cancer" @default.
• W88335433 cites W1485965660 @default.
• W88335433 cites W1494567425 @default.
• W88335433 cites W1497290886 @default.
• W88335433 cites W1512634984 @default.
• W88335433 cites W1536223993 @default.
• W88335433 cites W1541516070 @default.
• W88335433 cites W1546821979 @default.
• W88335433 cites W1556791620 @default.
• W88335433 cites W1564577788 @default.
• W88335433 cites W1571487648 @default.
• W88335433 cites W1576139194 @default.
• W88335433 cites W1584018958 @default.
• W88335433 cites W1594899067 @default.
• W88335433 cites W1597741096 @default.
• W88335433 cites W1608221503 @default.
• W88335433 cites W1673346837 @default.
• W88335433 cites W1784787521 @default.
• W88335433 cites W1876033686 @default.
• W88335433 cites W1876419231 @default.
• W88335433 cites W1913092726 @default.
• W88335433 cites W1925841406 @default.
• W88335433 cites W1965680643 @default.
• W88335433 cites W1966899954 @default.
• W88335433 cites W1967740144 @default.
• W88335433 cites W1967989739 @default.
• W88335433 cites W1970548320 @default.
• W88335433 cites W1970629830 @default.
• W88335433 cites W1972486937 @default.
• W88335433 cites W1973343777 @default.
• W88335433 cites W1973881587 @default.
• W88335433 cites W1974024894 @default.
• W88335433 cites W1974128576 @default.
• W88335433 cites W1975120553 @default.
• W88335433 cites W1975577875 @default.
• W88335433 cites W1976491209 @default.
• W88335433 cites W1977455576 @default.
• W88335433 cites W1977706798 @default.
• W88335433 cites W1977737642 @default.
• W88335433 cites W1978490353 @default.
• W88335433 cites W1979385264 @default.
• W88335433 cites W1982028980 @default.
• W88335433 cites W1982550220 @default.
• W88335433 cites W1984453879 @default.
• W88335433 cites W1984621921 @default.
• W88335433 cites W1987053905 @default.
• W88335433 cites W1988521127 @default.
• W88335433 cites W1988848379 @default.
• W88335433 cites W1990087411 @default.
• W88335433 cites W1992187858 @default.
• W88335433 cites W1993584147 @default.
• W88335433 cites W1993822264 @default.
• W88335433 cites W1994137567 @default.
• W88335433 cites W1994309500 @default.
• W88335433 cites W1995602629 @default.
• W88335433 cites W199786479 @default.
• W88335433 cites W1998255137 @default.
• W88335433 cites W1999996757 @default.
• W88335433 cites W2000000810 @default.
• W88335433 cites W2001363990 @default.
• W88335433 cites W2001954506 @default.
• W88335433 cites W2002127663 @default.
• W88335433 cites W2003003494 @default.
• W88335433 cites W2006360922 @default.
• W88335433 cites W2009671993 @default.
• W88335433 cites W2009948823 @default.
• W88335433 cites W2010255447 @default.
• W88335433 cites W2010881117 @default.
• W88335433 cites W2013381560 @default.
• W88335433 cites W2013498522 @default.
• W88335433 cites W2014469052 @default.
• W88335433 cites W2015201969 @default.
• W88335433 cites W2016701198 @default.
• W88335433 cites W2016975357 @default.
• W88335433 cites W2017020944 @default.
• W88335433 cites W2019124470 @default.
• W88335433 cites W2022207967 @default.
• W88335433 cites W2023399521 @default.
• W88335433 cites W2023487301 @default.
• W88335433 cites W2023568503 @default.
• W88335433 cites W2024448154 @default.
• W88335433 cites W2025018535 @default.
• W88335433 cites W2025338468 @default.
• W88335433 cites W2026317629 @default.
• W88335433 cites W2026431475 @default.
• W88335433 cites W2026522703 @default.
• W88335433 cites W2027711161 @default.
• W88335433 cites W2027810531 @default.
• W88335433 cites W2027925208 @default.
• W88335433 cites W2028337591 @default.
• W88335433 cites W2029598464 @default.
• W88335433 cites W2031465452 @default.
• W88335433 cites W2031953192 @default.
• W88335433 cites W2032353883 @default.
• W88335433 cites W2032564504 @default.

• next